The effect of the plasminogen activator inhibitor-1 4G/5G polymorphism on the thrombotic risk.
Plasminogen activator inhibitor (PAI-1), is the central component of the fibrinolytic system. A deletion/insertion (4G/5G) polymorphism in the promoter region of the PAI-1 gene has been correlated with levels of plasma PAI-1. The 4G allele is associated with higher levels of PAI-1, and might increase the risk for intravascular thrombosis. However, the contribution of this genetic variant to the risk for thrombosis, both arterial and venous, has not been clearly established. A broad spectrum of findings regarding the effect of the 4G allele on thrombotic risk in different target organs has been reported. Our aim is to summarize the variable influence of this polymorphism on thrombotic events in different tissues or organs and explain the underlying mechanisms accounting for these differences.
Tsantes
Argirios E
AE
Laboratory of Hematology & Blood Bank Unit, Attikon General Hospital, School of Medicine, University of Athens, Greece. atsantes@yahoo.com
Nikolopoulos
Georgios K
GK
Bagos
Pantelis G
PG
Bonovas
Stefanos
S
Kopterides
Petros
P
Vaiopoulos
Georgios
G
D002545:Brain Ischemia / Q000209:etiology / Q000235:genetics; D006801:Humans; D017395:Plasminogen Activator Inhibitor 1 / Q000235:genetics*; D011110:Polymorphism, Genetic; D011379:Prognosis; D020521:Stroke / Q000209:etiology / Q000235:genetics; D013927:Thrombosis / Q000209:etiology / Q000235:genetics*; D054556:Venous Thromboembolism / Q000209:etiology / Q000235:genetics
D017395:Plasminogen Activator Inhibitor 1